Lilly invests across all insulin sites in prep for diabetes epidemic
Eli Lilly is investing over $700m (€518m) at a number of its insulin producing sites globally saying it is a response to the “growing diabetes epidemic.”
Archives for November 20, 2013
Simulation offers cheaper more objective monitoring of CRAs, firm says
CRA Assessments says its standardised simulation approach to clinical trial monitors is a novel way for CROs and pharma firms to save costs and ensure quality.